Personalized lung cancer prevention

http://www.ncbi.nlm.nih.gov/pubmed/21733817

Cancer Prev Res (Phila). 2011 Jul;4(7):949-53.
The dawn of a revolution in personalized lung cancer prevention.
Khuri FR.
Source
FACP, Chair, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, NE, Atlanta, GA 30322. fkhuri@emory.edu.

Abstract
Lung cancer prevention and early detection, which have fallen on hard times for more than the past 20 years, seem to have turned a corner toward better times ahead. Exciting new results of randomized controlled trials that targeted the arachidonic acid pathway, including a celecoxib trial reported by Mao and colleagues in this issue of the journal (beginning on page 984) and a trial of the prostacyclin analog iloprost, complement recently reported 20%-30% lung cancer mortality reductions, either with aspirin in targeting the arachidonic acid pathway or with computed tomography screening. The new results show encouraging activity personalized to former smokers and/or people expressing predictive biomarkers. These trials and technological advances in molecular profiling and imaging herald substantial clinical advances on the horizon of this field. Cancer Prev Res; 4(7); 949-53. ©2011 AACR.